Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Chugai Mulling Japan Actemra Trial for COVID-19; Sanofi Says No Kevzara Plan for Now
March 24, 2020
-
REGULATORY Product Coverage Is the Biggest Theme for Off-Year Re-Pricing Debate: MHLW Official
March 23, 2020
-
BUSINESS (Update) Japan Approves Novartis’ SMA Gene Therapy Zolgensma; 15-20 Patients Expected Annually
March 19, 2020
-
ACADEMIA Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
-
BUSINESS Post-Promotion Guidelines - 1: Drug Makers Struggling to Establish Non-Sales Criteria for Rep Performance Review
March 18, 2020
-
BUSINESS Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
-
ORGANIZATION Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA
March 16, 2020
-
BUSINESS Coronavirus Woes Stymie Drug Makers’ Sales Activities in Japan, Curbs on Doctor Visits Continue
March 13, 2020
-
COMMENTARY Lenvima Heading into Megablockbuster Territory, Will Merck Tie-Up Help It Top Combined Aricept/Pariet Sales?
March 12, 2020
-
BUSINESS Drug Makers Calling Off Welcoming Ceremonies for New Hires over Coronavirus
March 11, 2020
-
REGULATORY Japan Cabinet OKs Bill to Allow Govt to Declare Emergency over Coronavirus
March 11, 2020
-
BUSINESS Japan’s 2020 Price Revision Hits Major Drugs with Double-Digit Slashes: Top 5 Product Survey
March 10, 2020
-
BUSINESS Japan’s Big 3 Generic Makers See 12.2% Price Cut vs. FY2018: Jiho Poll
March 9, 2020
-
BUSINESS Chugai, Teijin Suffer Hefty 9% Cuts in 2020 Drug Price Revision: Jiho Poll
March 6, 2020
-
REGULATORY Xolair Faces 37.3% Price Slash, Keytruda 20.9% in April: MHLW
March 5, 2020
-
BUSINESS Sumitomo Dainippon Creates Chief Scientific Officer Post to Optimize Portfolio
March 4, 2020
-
BUSINESS Vital-Net to Create 20-Strong Team of “Regenerative Medicine Liaisons”
March 3, 2020
-
BUSINESS Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections
March 2, 2020
-
BUSINESS MSD Japan Embarking on 2-Step Spinoff for Women’s Health, Legacy Brands
February 28, 2020
-
BUSINESS Japan Drug Makers Fearing Manufacturing Crisis as Coronavirus Spreads
February 27, 2020
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…